Item 8.01. Other Events. On August 17, 2026, Illumina, Inc. (“Illumina” or the “Company”) completed a public offering of $300,000,000 aggregate principal amount of its 4.950% notes due 2029 (the “Notes”).…
Filed Aug 17, 2026Accepted Aug 17, 2026, 4:02 PM EDTCIK 1110803Accession 0001193125-26-354010
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events.
On August 17, 2026, Illumina, Inc. (“Illumina” or the “Company”) completed a public offering of $300,000,000 aggregate principal amount of its 4.950% notes due 2029 (the “Notes”).
Illumina expects to use the net proceeds from the offering, together with cash on hand, to repay its 4.650% notes due September 9, 2026, of which $500 million aggregate principal amount was outstanding as of June 28, 2026.
The Notes were issued pursuant to an Indenture (the “Indenture”), dated March 12, 2021, between the Company and U.S. Bank Trust Company, National Association, as successor in interest to U.S. Bank National Association, as trustee, and an officer’s certificate establishing the terms of the Notes (which includes the form of Notes as an exhibit). The offering of the Notes was registered on a Registration Statement on Form S-3 (File No. 333-281921). The Notes will accrue interest at a rate of 4.950% per annum, payable semi-annually, and will mature on September 19, 2029.
Upon occurrence of an Event of Default (as defined in the Indenture) with respect to the Notes, the principal amount of the Notes may be declared, and/or become, due and payable immediately. The Company may, at its election, redeem the Notes, in whole or in part, from time to time at the redemption prices and on the terms and conditions set forth in the Notes.
The above description of the Notes is qualified in its entirety by reference to the Indenture, the officer’s certificate and the form of the Notes filed as exhibits hereto, which exhibits are incorporated by reference herein.
Filed exhibits (1)
EX-4.2 (by filename) d51146dex42.htm
EX-4.2
2
d51146dex42.htm
EX-4.2
EX-4.2
Exhibit 4.2
ILLUMINA, INC.
OFFICER’S CERTIFICATE
August 17, 2026
Reference is made to the Indenture dated as of March 12, 2021 (as so supplemented by this Officer’s Certificate, the
“Indenture”) by and between Illumina, Inc. (the “Issuer”) and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), as trustee (the
“Trustee”). The Trustee is the trustee for any and all Securities issued under the Indenture. Pursuant to Section 2.01 and Section 2.03 of the Indenture, the undersigned officer does hereby certify, in connection with
the establishment and the issuance of a series of Securities designated as the Issuer’s 4.950% Notes due 2029 (the “Notes”), that (i) the form and terms of the Notes have been established pursuant to Section 2.01
and Section 2.03 of the Indenture and comply with the Indenture, and (ii) the terms of the Notes are as follows:
Capitalized
terms used but not otherwise defined herein shall have the meanings specified in the Indenture.
Title: 4.950% Notes due 2029
Issuer: …